MCA205 cancers treated with (R)-crizotinib, alone or together with CDDP, exhibited a significant increase (p < 0.001, ANOVA test) in the local presence of activated dendritic cells (DC) expressing CD11c and CD86 (Supplementary Fig. 9a, d), CTL (Supplementary Fig. 9b, e). This evidence concerns the gene ITGAX and cancer.